

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/18881</b> (43) International Publication Date: 6 April 2000 (06.04.00)
<p>(21) International Application Number: PCT/US99/22776</p> <p>(22) International Filing Date: 30 September 1999 (30.09.99)</p> <p>(30) Priority Data: 60/102,413 30 September 1998 (30.09.98) US</p> <p>(71) Applicant (for all designated States except US): NEW ENGLAND BIOLABS, INC. [US/US]; 32 Tozer Road, Beverly, MA 01915 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): XU, Ming-Qun [US/CN]; 40 Crescent Road, Hamilton, MA 01982 (US). EVANS, Thomas, C. [US/US]; 1st floor, 68 Albion Street, Somerville, MA 02143 (US).</p> <p>(74) Agent: WILLIAMS, Gregory, D.; New England Biolabs, Inc., 32 Tozer Road, Beverly, MA 01915 (US).</p>		<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b> —</p> <p><i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: INTEIN MEDIATED PEPTIDE LIGATION</p> <p>(57) Abstract</p> <p>In accordance with the present invention, there is provided a method for producing a semi-synthetic fusion protein <i>in vitro</i>, comprising the steps of producing a target protein fused to a protein splicing element (an intein) and selectively cleaving the fusion and ligating a synthetic protein or peptide at the C-terminal thioester of the target protein, which overcome many of the disadvantages and problems noted above. Specifically, the present invention has higher yields due to better thiol-induced cleavage with thiol-reagents which have been optimized for the ligation reaction, off-column ligation allows sample concentration and allows the use of less peptide, MESNA is an odorless thiol-reagent for ligation, and Mxe intein is from a bacterial source and often expresses better in bacterial cells. Furthermore, the present invention allows peptides to be directly ligated to the thioester bond formed between an intein and the target protein. The present invention also provides a method for producing a cytotoxic protein, comprising the steps of producing a truncated, inactive form of the protein <i>in vivo</i> which is fused to a protein splicing element, and selectively cleaving the fusion and ligating a synthetic protein or peptide at a C-terminal thioester of the target protein to restore the activity of the native cytotoxic protein. Recombinant vectors for producing such cleavable fusion proteins are also provided.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INTEIN MEDIATED PEPTIDE LIGATION

### BACKGROUND OF THE INVENTION

5           Genetic engineering is a powerful approach to the manipulation of proteins. However, genetic methodologies are constrained by the use of only naturally coded amino acids. Furthermore, cytotoxic proteins are difficult to obtain by expression and isolation from a living source, since the  
10           expression of the toxic protein can result in death of the host.

          To some extent, protocols have been developed to circumvent these problems, for example, total chemical synthesis (Kent, S. B. (1988) *Ann. Rev. Biochem.* 57:957-989),  
15           use of misacylated tRNAs (Noren, et al., (1989) *Science* 244:182-188), and semi-synthetic techniques (reviewed in Offord, R. (1987) *Protein Eng.* 1:151-157; Roy. et al. (1994) *Methods in Enzymol.* 231:194-215; Wallace, C. J. (1993) *FASEB* 7:505-515). However, all of these procedures are limited by  
20           either the size of the fragment which can be generated or by low reaction yield.

          It would therefore be desirable to develop a high-yield, semi-synthetic technique to allow *in vitro* fusion of a  
25           synthetic protein or peptide fragment to an expressed protein without limitation as to the size of the fused fragments.

Likewise, in order to produce cytotoxic proteins, it would be desirable to develop a method of fusing a synthetic fragment, *in vitro*, to an inactive, expressed protein, so as to restore protein activity post-production from the host.

The modified Sce VMA intein has been used to generate thioester-tagged proteins for use in ligation (Example 19, U.S.S.N. 08/811,492, filed June 16, 1997; Chong, (1996) *J. Biol. Chem.*, 271(36):22159-22168; Chong, (1997) *Gene*, 192:271-281; and Muir, et al. (1998) *Proc. Natl. Acad. Sci USA* 95:6705-6710).

Some disadvantages have been low yields due to poor cleavage of the Sce VMA intein with thiol-reagents that are optimum for ligation, the need for large peptide quantities due to on-column reactions, the use of odoriferous reagents, and/or low protein yields due to the use of a large, eukaryotic intein.

### SUMMARY OF THE INVENTION

In accordance with the present invention, there is provided a method for producing a semi-synthetic fusion protein *in vitro*, comprising the steps of producing a target protein fused to a protein splicing element (an intein) and selectively cleaving the fusion and ligating a synthetic

protein or peptide at the C-terminal thioester of the target protein, which overcome many of the disadvantages and problems noted above. Specifically, the present invention has higher yields due to better thiol-induced cleavage with thiol reagents which have been optimized for the ligation reaction. Off-column ligation allows for sample concentration as well as the use of less peptide. In a particularly preferred embodiment, thiol reagents such as 2-mercaptoethanesulfonic acid (MESNA), which is an odorless thiol-reagent, is used for cleavage and ligation along with the Mxe intein, which is from a bacterial source and often expresses better in bacterial cells. Furthermore, the present invention allows peptides to be directly ligated to the thioester bond formed between an intein and the target protein. The present invention also provides a method for producing a cytotoxic protein, comprising the steps of producing a truncated, inactive form of the protein *in vivo* which is fused to a protein splicing element, and selectively cleaving the fusion and ligating a synthetic protein or peptide at a C-terminal thioester of the target protein to restore the activity of the native cytotoxic protein. Recombinant vectors for producing such cleavable fusion proteins are also provided.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a flow diagram depicting the chemical reactions which enable intein-mediated peptide ligation. The

thioester generated at the C-terminus of the target protein during IMPACT™ purification was used in a 'native chemical ligation' reaction. This allowed the ligation of a synthetic peptide to a bacterially expressed protein. A typical ligation -  
5 reaction involved the expression of the target protein-intein-CBD fusion followed by binding to a chitin resin. A thiol reagent induced cleavage of the intein. The target was eluted from the chitin resin and a synthetic peptide was added. The ligation reaction proceeded overnight.

10

Figure 2 is a gel depicting the results of cleavage and ligation reactions using various thiols. Cleavage and ligation reactions with different thiols visualized on 10-20% Tricine gels. MYB (a fusion protein of maltose binding protein-Sce  
15 VMA intein (N454A)-chitin binding domain) and MXB (a fusion protein of maltose binding protein-Mxe GyrA (N198A) intein-chitin binding domain) were incubated overnight at 4°C with various thiols (50 mM) in 150 mM Tris, 100 mM NaCl, pH 8 in the presence of a 30 amino acid peptide with an N-terminal  
20 cysteine. The peptide ligates to the C-terminus of MBP. Lanes 1-5 ligation with MYB. Lane 1 no thiol. Lane 2 dithiothreitol. Lane 3 2-mercaptoethanesulfonic acid. Lane 4 3-mercaptopropionic acid. Lane 5 thiophenol. Lanes 6-10  
ligation with MXB. Lane 6 no thiol. Lane 7 dithiothreitol. Lane  
25 8 2-mercaptoethanesulfonic acid. Lane 9 3-mercaptopropionic acid. Lane 10 thiophenol.

Figure 3 is a gel depicting direct ligation of a peptide to the thioester formed between the Sce VMA intein and maltose binding protein. SDS-PAGE of direct ligation reaction with a 10-20% Tricine gel. Lane 1: a precursor protein (MYBleu) consisting of maltose binding protein-Sce VMA1 intein-chitin binding domain was heated to >95°C for 5 minutes in a buffer of 50 mM Trizma base, pH 8.5 containing 100 mM NaCl, 1% SDS, and mM tris-(2-carboxyethyl)phosphine (TCEP) followed by overnight incubation at room temperature. The precursor (MYBleu) is visible along with the Sce VMA1 intein (Y) and maltose binding protein (M), which are cleavage products. Lane 2: the precursor protein was subjected to the same conditions as described in Lane 1 except that the 30 amino acid peptide (1 mM) was added. The precursor (MYB) and cleavage products (Y and M) are visible along with the ligation product (M+30mer) formed when the 30 amino acid peptide fuses to maltose binding protein.

Figure 4 is a diagram depicting the pTXB1 expression vector of Example I (SEQ ID NO:7 and SEQ ID NO:8).

Figure 5 is the DNA sequence of pTXB1 (SEQ ID NO:5).

Figure 6 is a gel depicting the results of the *HpaI* protein ligation reaction. Protein ligation reactions examined on 10-20% Tricine gels. Lane 1: clarified cells extract after IPTG (0.5 mM) induction of ER2566 cells containing the pTXB2-*HpaI*

plasmid. The fusion protein of *HpaI*<sub>223</sub>-Mxe GyrA-intein-CBD (52 kDa) is visible. Lane 2: cell extract as in Lane 1 after passage over a chitin column, which results in the binding of the fusion protein. Lane 3: *HpaI*<sub>223</sub> (25.7 kDa) after cleavage from the fusion protein by addition of MESNA. Lane 4: ligation product of *HpaI*<sub>223</sub> (0.2 mg/mL) with 1 mM of a 31 amino acid peptide (ligation product 29.6 kDa), representing the residues necessary to generate full length *HpaI*, after overnight incubation at 4°C. Lane 5: full length *HpaI* from a recombinant source (29.6 kDa) containing BSA (66 kDa) and two impurities.

Figure 7 is a western blot of various proteins ligated to a biotinylated peptide. Proteins purified with the Mxe GyrA IMPACT™ derivative were ligated to a synthetic peptide which contained an antibody recognition sequence.

### **DETAILED DESCRIPTION OF THE INVENTION**

The ligation methods of the present invention are based on the discovery that a cysteine or peptide fragment containing an N-terminal cysteine may be fused, *in vitro*, to a bacterially expressed protein produced by thiol-induced cleavage of an intein (U.S. Patent No. 5,496,714; Example 19 of U.S.S.N. 08/811,492 filed June 16, 1997; Chong, et al., (1996) *supra* and Chong, et al., (1997) *supra*.



The ligation procedure disclosed herein utilizes a protein splicing element, an intein (Perler, et al., (1994) *Nucleic Acids Res.* 22:1125-1127) to precisely create a thioester at the C-terminal  $\alpha$ -carbon of an expressed protein. -

5 This reactive thioester could be present between the target protein and intein or generated by the addition of a thiol reagent. Previously the generation such a thioester was described using an intein (CIVPS) that was modified to undergo thiol inducible cleavage at its N-terminal junction in  
10 the presence of thiol reagent dithiothreitol (DTT) (Chong, et al. (1997) *supra*; Comb, et.al. U.S. Patent No. 5,496,714). This C-terminal thioester was previously used in a 'native chemical ligation' type reaction (Dawson, et al., (1994) *Science* 266:776-779) to fuse <sup>35</sup>S-cysteine or a peptide  
15 fragment containing an N-terminal cysteine to a bacterially expressed protein (Example 19, Comb, et.al. U.S. Patent No. 5,834,247, Chong (1996) *supra* and Chong (1997) *supra*.

The ligation method of the instant invention begins with  
20 the purification of the thioester-tagged target protein using an intein as described (Chong, et.al. (1997) *supra*). The direct ligation method of the instant invention begins with the isolation of a precursor composed of the target protein-intein-CBD. In one preferred embodiment, the host cell is  
25 bacterial. In other embodiments the host cell may be yeast, insect, or mammalian. A cysteine thiol at the N-terminus of a synthetic peptide nucleophilically attacks a thioester present

on the freshly isolated C-terminal  $\alpha$ -carbon of the target protein or directly attacks the thioester present between the target protein and intein. This initially generates a thioester between the two reactants which spontaneously rearranges  
5 into a native peptide bond (Figure 1).

In order to optimize the ligation efficiency so that greater than 90% of the bacterially expressed target protein can be fused to the synthetic peptide or protein, specific thiol  
10 reagents and inteins are screened. In a preferred embodiment, the intein may be any CIVPS, such as *Sce* VMA, *Mxe* GyrA or derivatives of mutants thereof, and the thiol reagent is 2-mercapto-ethanesulfonic acid, thiophenol, DTT, or 3-mercaptopropionic acid (Comb, et al., U.S. Patent No.  
15 5,496,714; U.S. Patent No. 5,834,247).

In one particularly preferred embodiment, an intein whose protein splicing activity has been blocked by mutation is utilized. The mutant must, however, retain the ability to  
20 undergo the N-S shift, thus allowing thioester formation between itself and an N-terminal protein. This thioester can then be nucleophilically attacked by a thiol reagent or by the N-terminal cysteine of a peptide sequence. For example, by mutating the C-terminal asparagine (asn 198) of an intein  
25 from the GyrA gene of *Mycobacterium xenopi* (Telenti, et al., (1997) *J Bacteriol* 179:6378-6382) to an alanine created a

thiol inducible cleavage element. This modified intein cleaved well with thiol reagents that were optimal for the ligation reaction, such as MESNA and thiophenol. Furthermore, optimal thiol reagent and intein combinations can be determined by incubating a precursor protein containing the intein of interest with a wide variety of thiol reagents followed by determination of the extent of cleavage of the precursor protein (Figure 2).

The use of such intein and specific thiol reagents leads to optimal yields and high ligation efficiencies; typically greater than 90% of the N-terminal ligation fragment can be modified.

The ligation methods of the present invention expand the ability to incorporate non-coded amino acids into large protein sequences by generating a synthetic peptide fragment with fluorescent probes, spin labels, affinity tags, radiolabels, or antigenic determinants and ligating this to an *in vivo* expressed protein isolated using a modified intein.

Furthermore, this procedure allows the isolation of cytotoxic proteins by purifying an inactive truncated precursor from a host source, for example bacteria, and generating an active protein or enzyme after the ligation of a synthetic peptide. For example, restriction endonucleases which have not successfully been cloned by traditional

methods may be produced in accordance with the present invention.

Also, the direct ligation procedure allows the ligation of -  
5 a protein or peptide sequence to another protein or peptide sequence without the use of exogenous thiol reagents. Direct ligation relies on the nucleophilic attack of the N-terminal amino acid of one peptide on the thioester formed between a target protein and an intein (Figure 3).

10 In summary, a fusion protein can be created using the methods of the present invention that possesses unique properties which, currently, can not be generated genetically.

15 The Examples presented below are only intended as specific preferred embodiments of the present invention and are not intended to limit the scope of the invention. The present invention encompasses modifications and variations of the methods taught herein which would be obvious to one of  
20 ordinary skill in the art.

The references cited above and below are herein incorporated by reference.

**EXAMPLE I****Creation of vectors pTXB1 and pTXB2 for ligation:**

5           Asparagine 198 of the *Mxe* GyrA intein (Telenti, et al.,  
(1997) *J Bacteriol.* 179:6378-6382) was mutated to alanine by  
linker insertion into the *XmnI* and *PstI* sites of  
pmxeMIPTyrXmnSPdel to create pMXP1. The *XmnI* site was  
originally introduced into the unmodified *Mxe* GyrA intein  
10           sequence by silent mutagenesis. The *PstI* site was a unique  
site in the plasmid. The linker was composed of mxe#3 (5'-  
GGTTCGTCAGCCACGCTACTGGCCTCACCGGTTGATAGCTGCA-3')  
(SEQ ID NO:1) and mxe#4 (5'-GCTATCAACCGGTGAGGCCAGTAG  
CGTGGCTGACGAACC-3') (SEQ ID NO:2).

15           Into pMXP1 another linker composed of mxe#1 (5'-TC  
GAATCTAGACATATGGCCATGGGTGGCGGCCGCTCGAGGGCTCTTCC  
TGCATCACGGGAGATGCA-3') (SEQ ID NO:3) and mxe#2 (5'-CTAG  
TGCATCTCCCGTGATGCAGGAAGAGCCCTCGAGGCGHGCGGCCACCCA  
20           TGGCCATATGTCTAGAT-3') (SEQ ID NO:4) was inserted into the  
*XhoI* and *SpeI* sites to introduce a multiple cloning site (*XbaI*-  
*NdeI*-*NcoI*-*NotI*-*XhoI*-*SapI*) before the *Mxe* GyrA intein (pMXP2).

          The 0.6 kilobase *NotI* to *AgeI* fragment of pMXP2 was  
25           ligated into the same sites in pTYB1 (IMPACT kit, New England  
Biolabs, Beverly, MA) and the *NcoI* to *AgeI* fragment of pMXP2

was cloned into pTYB3 (IMPACT kit, New England Biolabs, Beverly, MA) to create plasmids pTXB1 (see Figure 4 and 5) (SEQ ID NO:5) and pTXB2, respectively. These vectors have a multiple cloning site upstream of the modified *Mxe* GyrA intein-chitin binding domain fusion. This allows the insertion of a target gene of interest inframe with the intein and chitin binding domain (CBD).

#### **Creation of vectors pMYBleu for ligation:**

pMYBleu was as described in Chong, et al., (1998), *J. Biol. Chem.* 273:10567-10577. This vector consisted of maltose binding protein upstream of the *Sce* VMA intein-chitin binding domain. A leucine is present at the -1 position instead of the native residue (which is a glycine).

#### **Purification of Thioester-Tagged Proteins:**

Protein purification was as described using the *Sce* VMA intein (Chong, et.al., (1997) *Gene* 192:271-281) with slight modification. ER2566 cells (IMPACT T7 instruction manual from New England Biolabs, Beverly, MA) containing the pTXB vector with the appropriate insert were grown to an OD<sub>600</sub> of 0.5-0.6 at 37°C at which point they were induced with 0.5 mM IPTG overnight at 15°C. Cells were harvested by centrifugation and lysed by sonication (performed on ice). The

three part fusion protein was bound to chitin beads (10 mL bed volume, Figure 6, lanes 1 and 2) equilibrated in Buffer A (50 mM Tris, pH 7.4, and 500 mM NaCl), and washed with 10 column volumes of Buffer A to remove unbound material.

5

Cleavage was initiated using a buffer of 50 mM 2-mercaptoethanesulfonic acid (MESNA), 50 mM Tris, pH 8.0 and 100 mM NaCl. Other thiol reagents were also used at other times, such as thiophenol, dithiothreitol, and/or 3-mercaptopropionic acid. After overnight incubation at from 4-25°C protein was eluted from the column (Figure 6 lane 3). This protein contained a thioester at the C-terminus.

10

#### **Purification of MYB, MYBleu and MXB:**

15

Full length precursor proteins consisting of maltose binding protein-*Sce* VMA intein (N454A)-chitin binding domain (MYB) and maltose binding protein-*Mxe* GyrA (N198A) intein-chitin binding domain (MXB) were purified after induction and sonication, as described above, by applying the sonicated sample to a 10 mL column of amylose resin (New England Biolabs, Beverly, MA). Unbound proteins were washed from the column with 10 column volumes of Buffer A (see purification of thioester-tagged proteins). Bound proteins were eluted with a buffer of 50 mM Tris, pH 8, containing 100 mM NaCl and 10 mM maltose. Fractions were collected and protein

20

25

concentrations were determined using the Bio-Rad Protein Assay (Hercules, CA).

### Peptide Synthesis:

5

Peptides for subsequent ligation reactions were synthesized on an ABI model 433A peptide synthesizer utilizing *FastMoc*<sup>™</sup> chemistry (Fields, et al., (1991) *Pept Res* 4, 95-101) at a 0.085 mmol scale. Preloaded HMP (p-  
10 hydroxymethylphenoxymethyl) polystyrene resins (Applied Biosystems, Foster City, CA) functionalized at 0.5 mmol/g was used in conjunction with Fmoc/NMP chemistry utilizing HBTU amino acid activation (Dourtoglou, et al., (1984) *Synthesis* 572-574; Knorr, et al., (1989) *Tetrahedron Lett* 30,  
15 1927-1930). Fmoc amino acids were purchased from Applied Biosystems (Foster City, CA).

Synthesis proceeded with a single coupling during each cycle. Peptide cleavage from the resin and simultaneous  
20 removal of side chain protecting groups was facilitated by the addition of cleavage mixture (Perkin Elmer, Norwalk, CT) consisting of 0.75 g phenol, 0.25 mL 1,2-ethanedithiol, 0.5 mL deionized H<sub>2</sub>O, and 10 mL TFA. The resin was flushed with nitrogen and gently stirred at room temperature for 3 hours.  
25 Following filtration and precipitation into cold (0°C) methyl-t-butyl ether, the precipitate in the ether fraction was



collected by centrifugation. The peptide precipitate was vacuum dried and analyzed by mass spectrometry using a Perceptive Biosystems (Framingham, MA) MALDI-TOF mass spectrometer.

5

Final purification was by HPLC using a Waters HPLC system with a Lambda-Max Model 481 Multiwavelength detector (set at 214 nm), 500 series pumps and automated gradient controller with a Vydac semi-preparative C18 column. Elution of the peptide was with a 60 minute linear gradient of 6-60% acetonitrile (v/v) in an aqueous solution of 0.1% TFA (v/v).

10

#### **Protein Cleavage and Ligation Reactions:**

15

Cleavage of MYB and MXB: The precursor protein (1 mg/mL) was incubated overnight at 4°C with or without a thiol reagent (50 mM) in 150 mM Tris, pH 8, containing 100 mM NaCl.

20

Ligation reactions with MYB and MXB: The precursor protein (1 mg/mL) was treated as described for cleavage except that a 30 amino acid peptide (1 mM final concentration, NH<sub>2</sub>-CAYKTTQANKHIIIVACEGNPYVPVHFDASV-COOH (SEQ ID NO:6) was also included in the reaction (Figure 2).

25

Ligation reactions after purification of thioester-tagged proteins: Lyophilized peptides (New England Biolabs, Beverly, MA) were added (to 1 mM final concentration) directly to the thioester-tagged protein freshly isolated from the chitin column. The reaction was allowed to proceed overnight at from 4-25°C. In both ligation procedures the condensation of the reactants is visible on a 10-20% Tricine gel (Figure 6). The ligation reaction was tested in conditions of 5-150 mM Tris or HEPES buffers, 50-1000 mM NaCl, 10 mM Maltose, and pH 6-11 and 0-6 M Urea.

#### **Direct Ligation Reactions:**

MYBleu (1 mg/mL) was incubated in 6 M Urea or 1% SDS, pH 7.5-8.5, 50-200 mM NaCl, and 1 mM of a 30 amino acid peptide (NH<sub>2</sub>CAYKTTQANKHIVVACEGNPYVPVHFDASV-COOH (SEQ ID NO:6)). The MYBleu was incubated for 0-180 minutes at either 4°C or 100°C prior to the addition of the 30 amino acid peptide. Ligation reactions proceeded overnight at either 4°C or 25°C.

## **EXAMPLE II**

### **Labeling a target protein: Maltose Binding Protein**

5           Maltose binding protein (MBP, 42 kDa) was isolated as described in Example I above using the IMPACT procedure (IMPACT manual from New England Biolabs, Inc., Beverly, MA) in the presence of MESNA.

10           A biotinylated peptide possessing an N-terminal cysteine (CDPEK\*DS-COOH (SEQ ID NO:9)), in which the biotin was attached to the  $\epsilon$ -amino group of the lysine residue) was ligated to the freshly purified target protein as described above. Briefly, 4  $\mu$ L of biotinylated peptide (10 mM) were  
15 mixed with a 36  $\mu$ L aliquot of the freshly purified MBP sample. The mixture was incubated at 4°C overnight.

          Western blots with alkaline phosphatase linked anti-biotin antibody detected the presence of the ligated product  
20 but not the unligated target protein (Figure 7). The efficiency of the ligation is typically greater than 90% when MESNA is used for cleavage.

### EXAMPLE III

#### **Labeling a target protein: Bst DNA Polymerase I Large Fragment (Bst Pol 1)**

5

Bst DNA Polymerase I large fragment (67 kDa) was isolated as described in Example I above using the IMPACT procedure (IMPACT manual from New England Biolabs, Inc., Beverly, MA) in the presence of MESNA.

10

A biotinylated peptide possessing an N-terminal cysteine (CDPEK\*DS-COOH (SEQ ID NO:9)), in which the biotin was attached to the  $\epsilon$ -amino group of the lysine residue) was ligated to the freshly purified target protein as described.

15

Briefly, 4  $\mu$ L of biotinylated peptide (10 mM) were mixed with a 36  $\mu$ L aliquot of the freshly purified Bst Pol 1 sample. The mixture was incubated at 4°C overnight.

20

Western blots with alkaline phosphatase linked anti-biotin antibody detected the presence of the ligated product but not the unligated target protein (Figure 7). The efficiency of the ligation is typically greater than 90% when MESNA is used for cleavage.

**EXAMPLE IV****Labeling a target protein: Paramyosin**

5           Paramyosin (29 kDa) was isolated as described in Example I above using the IMPACT procedure (IMPACT manual from New England Biolabs, Inc., Beverly, MA) in the presence of MESNA.

10           A biotinylated peptide possessing an N-terminal cysteine (CDPEK\*DS-COOH (SEQ ID NO:9)), in which the biotin was attached to the  $\epsilon$ -amino group of the lysine residue) was ligated to the freshly purified target protein as described. Briefly, 4  $\mu$ L of biotinylated peptide (10 mM) were mixed with  
15           a 36  $\mu$ L aliquot of the freshly purified paramyosin sample. The mixture was incubated at 4°C overnight.

          Western blots with alkaline phosphatase linked anti-biotin antibody detected the presence of the ligated product  
20           but not the unligated target protein (Figure 7). The efficiency of the ligation is typically greater than 90% when MESNA is used for cleavage.

**EXAMPLE V****Labeling a target protein: *E. coli* Thioredoxin**

5           *E. coli* thioredoxin (12 kDa) was isolated as described in Example I above using the IMPACT procedure (IMPACT manual from New England Biolabs, Inc., Beverly, MA) in the presence of MESNA.

10           A biotinylated peptide possessing an N-terminal cysteine (CDPEK\*DS-COOH (SEQ ID NO:9)), in which the biotin was attached to the  $\epsilon$ -amino group of the lysine residue) was ligated to the freshly purified target protein as described. Briefly, 4  $\mu$ L of biotinylated peptide (10 mM) were mixed with  
15           a 36  $\mu$ L aliquot of the freshly purified thioredoxin sample. The mixture was incubated at 4°C overnight.

            Western blots with alkaline phosphatase linked anti-biotin antibody detected the presence of the ligated product  
20           but not the unligated target protein (Figure 7). The efficiency of the ligation is typically greater than 90% when MESNA is used for cleavage.

**EXAMPLE VI****Isolation of a cytotoxic protein:**

5           The ligation procedure of Example I was applied to the isolation of a potentially cytotoxic protein. An endonuclease from *Haemophilus parainfluenzae* (*HpaI*; Ito, et al., (1992) *Nucleic Acids Res* 20:705-709) was generated by ligating an inactive truncated form of the enzyme expressed in *E. coli*  
10           (ER2566 cells, New England Biolabs, Inc., Beverly, MA) with the missing amino acids that were synthesized chemically.

          The first 223 amino acids of *HpaI* (full length *HpaI* is 254 amino acids) were fused in frame with the modified *Mxe*  
15           GyrA intein and the CBD. The 223 amino acid *HpaI* fragment was isolated as described for purification of thioester tagged proteins. The truncated *HpaI* displayed no detectable enzymatic activity.

20           A synthetic peptide representing the 31 amino acids needed to complete *HpaI* was ligated onto the 223 amino acid truncated form of *HpaI* by the method of Example I.

**Enzymatic Assay for *Hpa*I:**

5       The activity of the fused *Hpa*I was determined by its ability to digest Lambda DNA (New England Biolabs, Beverly, MA). Serial dilutions of ligated or truncated *Hpa*I, with the appropriate peptide added to 1 mM, were incubated with 1  $\mu$ g of Lambda DNA for 1 hour at 37°C in a buffer of 20 mM Tris-acetate, pH 7.9, 10 mM magnesium acetate, 50 mM potassium acetate, 1 mM dithiothreitol, and 170  $\mu$ g/mL BSA (total  
10       volume 30  $\mu$ L). Digestion reactions were visualized on 1% agarose gels permeated with ethidium bromide. One unit of *Hpa* I was defined as the amount of enzyme necessary to digest 1  $\mu$ g of Lambda DNA in one hour at 37°C.

15       The newly ligated *Hpa*I had a specific activity of 0.5-1.5x10<sup>6</sup> units/mg which correlated well with the expected value of 1-2x10<sup>6</sup> units/mg for the full length enzyme.



**WHAT IS CLAIMED IS:**

1. A method for fusing an expressed protein with a peptide,  
said method comprising the steps of:
  - 5 (a) generating at least one C-terminal thioester-tagged target protein;
  - (b) generating at least one target peptide having a specified N-terminal; and
  - (c) ligating said target peptide to said target protein.
- 10 2. The method of claim 1, wherein said target protein is generated from a first plasmid comprising an intein having N-terminal cleavage activity.
- 15 3. The method of claim 2, wherein said intein comprises an intein having a cysteine residue at the N-terminal of the intein.
- 20 4. The method of claim 3, wherein said target protein is generated by thiol reagent-induced cleavage of said intein.
- 25 5. The method of claim 4, wherein said thiol reagent is selected from the group consisting of MESNA, thiophenol, DTT,  $\beta$ -mercaptoethanol or derivatives thereof.
6. A fusion protein produced by the method of any one of claims 1-5.

7. A cyclic protein produced by the method of claim 1.
- 5 8. A modified intein comprising a mutant Mxe GyrA intein capable of thiol reagent-induced cleavage to produce a thioester at the C-terminal of an adjacent target protein.
- 10 9. A method of generating a reactive thioester comprising contacting a thiol reagent selected from the group consisting essentially of MESNA, thiophenol, DTT,  $\beta$ -mercaptoethanol or derivatives thereof with a precursor comprising a target protein and intein.
- 15 10. A method for screening thiol reagents which cleave a target intein comprising the steps of:
  - (a) isolating a precursor comprising a protein and a modified intein;
  - 20 (b) contacting a thiol reagent with the precursor of step (a);
  - (c) determining whether a splicing or cleaving event occurs.
- 25 11. The method of claim 10, comprising the further step of determining whether the spliced or cleaved product of step (c) can ligate to a target peptide having an N-terminal cytokine.

Figure 1

Intein Mediated Protein Ligation




Figure 2






Figure 3. Direct Ligation Reaction



# pTXB1 Expression Vector

Figure 4



## pTXB1

....Met Ala Met Gly Gly Gly Arg Leu Glu Gly Ser Ser Cys1...Intein  
CAT ATG GCC ATG GGT GGC GGC CGC CTC GAG GGC TCT TCC TGC  
 NdeI NcoI NotI XhoI SspI

Figure 5

1 AACTACGTCA GGTGGCACTT TTCGGGGAAA TGTGCGCGGA ACCCCTATTT  
51 GTTTATTTTT CTAAATACAT TCAAATATGT ATCCGCTCAT GAGACAATAA  
101 CCCTGATAAA TGCTTCAATA ATATTGAAAA AGGAAGAGTA TGAGTATTCA  
151 ACATTTCCGT GTCGCCCTTA TTCCCTTTTT TGCGGCATT TGCCTTCCTG  
201 TTTTGTCTCA CCCAGAAACG CTGGTGAAAG TAAAAGATGC TGAAGATCAG  
251 TTGGGTGCAC GAGTGGGTTA CATCGAACTG GATCTCAACA GCGGTAAGAT  
301 CCTTGAGAGT TTTGCCCCG AAGAACGTTT TCCAATGATG AGCACTTTTA  
351 AAGTTCTGCT ATGTGGCGCG GTATTATCCC GTGTTGACGC CGGGCAAGAG  
401 CAACTCGGTC GCCGCATACA CTATTCTCAG AATGACTTGG TTGAGTACTC  
451 ACCAGTCACA GAAAAGCATC TTACGGATGG CATGACAGTA AGAGAATTAT  
501 GCAGTGCTGC CATAACCATG AGTGATAACA CTGCGGCCAA CTTACTTCTG  
551 ACAACGATCG GAGGACCGAA GGAGCTAACC GCTTTTTTGC ACAACATGGG  
601 GGATCATGTA ACTCGCCTTG ATCGTTGGGA ACCGGAGCTG AATGAAGCCA  
651 TACCAAACGA CGAGCGTGAC ACCACGATGC CTGTAGCAAT GGCAACAACG  
701 TTGCGCAAAC TATTAAGTGG CGAACTACTT ACTCTAGCTT CCCGGCAACA  
751 ATTAATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA CTTCTGCGCT  
801 CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG  
851 CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC

901 CCGTATCGTA GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC  
951 GAAATAGACA GATCGCTGAG ATAGGTGCCT CACTGATTAA GCATTGGTAA  
1001 CTGTCAGACC AAGTTTACTC ATATATACTT TAGATTGATT TACCCCGGTT  
1051 GATAATCAGA AAAGCCCCAA AACAGGAAG ATTGTATAAG CAAATATTTA  
1101 AATTGTAAAC GTTAATATTT TGTTAAAATT CGCGTTAAAT TTTTGTAAAA  
1151 TCAGCTCATT TTTTAACCAA TAGGCCGAAA TCGGCAAAAT CCCTTATAAA  
1201 TCAAAAGAAT AGCCCCGAGAT AGGGTTGAGT GTTGTTCCAG TTTGGAACAA  
1251 GAGTCCACTA TTAAAGAACG TGGACTCCAA CGTCAAAGGG CGAAAAACCG  
1301 TCTATCAGGG CGATGGCCCA CTACGTGAAC CATCACCCAA ATCAAGTTTT  
1351 TTGGGGTCGA GGTGCCGTAA AGCACTAAAT CGGAACCCTA AAGGGAGCCC  
1401 CCGATTTAGA GCTTGACGGG GAAAGCCGGC GAACGTGGCG AGAAAGGAAG  
1451 GGAAGAAAGC GAAAGGAGCG GGCCTAGGG CGCTGGCAAG TGTAGCGGTC  
1501 ACGCTGCGCG TAACCACCAC ACCCGCCGCG CTTAATGCGC CGCTACAGGG  
1551 CGCGTAAAAG GATCTAGGTG AAGATCCTTT TTGATAATCT CATGACCAAA  
1601 ATCCCTTAAC GTGAGTTTTT GTTCCACTGA GCGTCAGACC CCGTAGAAAA  
1651 GATCAAAGGA TCTTCTTGAG ATCCTTTTTT TCTGCGCGTA ATCTGCTGCT  
1701 TGCAAACAAA AAAACCACCG CTACCAGCGG TGGTTTGTTT GCCGGATCAA  
1751 GAGCTACCAA CTCTTTTTC GAAGGTA ACT GGCTTCAGCA GAGCGCAGAT  
1801 ACCAAATACT GTCCTTCTAG TGTAGCCGTA GTTAGGCCAC CACTTCAAGA  
1851 ACTCTGTAGC ACCGCCTACA TACCTCGCTC TGCTAATCCT GTTACCAGTG  
1901 GCTGCTGCCA GTGGCGATAA GTCGTGTCTT ACCGGGTTGG ACTCAAGACG  
1951 ATAGTTACCG GATAAGGCGC AGCGGTCGGG CTGAACGGGG GGTTCGTGCA  
2001 CACAGCCCAG CTTGGAGCGA ACGACCTACA CCGAACTGAG ATACCTACAG  
2051 CGTGAGCTAT GAGAAAGCGC CACGCTTCCC GAAGGGAGAA AGGCGGACAG  
2101 GTATCCGGTA AGCGGCAGGG TCGGAACAGG AGAGCGCACG AGGGAGCTTC  
2151 CAGGGGGAAA CGCCTGGTAT CTTTATAGTC CTGTCGGGTT TCGCCACCTC  
2201 TGA CTGAGC GTCGATTTTT GTGATGCTCG TCAGGGGGGC GGAGCCTATG  
2251 GAAAAACGCC AGCAACGCGG CCTTTTTACG GTTCCTGGCC TTTTGCTGGC  
2301 CTTTGTCTCA CATGTTCTTT CCTGCGTTAT CCCCTGATTC TGTGGATAAC




2351 CGTATTACCG CCTTTGAGTG AGCTGATACC GCTCGCCGCA GCCGAACGAC  
2401 CGAGCGCAGC GAGTCAGTGA GCGAGGAAGC TATGGTGCAC TCTCAGTACA  
2451 ATCTGCTCTG ATGCCGCATA GTTAAGCCAG TATACACTCC GCTATCGCTA  
2501 CGTGA CTGGG TCATGGCTGC GCGCCGACAC CCGCCAACAC CCGCTGACGC  
2551 GCCCTGACGG GCTTGTCTGC TCCCGGCATC CGCTTACAGA CAAGCTGTGA  
2601 CCGTCTCCGG GAGCTGCATG TGTCAGAGGT TTTCACCGTC ATCACCGAAA  
2651 CGCGCGAGGC AGCTGCGGTA AAGCTCATCA GCGTGGTCGT GCAGCGATTG  
2701 ACAGATGTCT GCCTGTTCAT CCGCGTCCAG CTCGTTGAGT TTCTCCAGAA  
2751 GCGTTAATGT CTGGCTTCTG ATAAAGCGGG CCATGTTAAG GGCGGTTTTT  
2801 TCCTGTTTGG TCACTTGATG CCTCCGTGTA AGGGGAATT TCTGTTTCATG  
2851 GGGGTAATGA TACCGATGAA ACGAGAGAGG ATGCTCACGA TACGGGTTAC  
2901 TGATGATGAA CATGCCCGGT TACTGGAACG TTGTGAGGGT AAACAAC TGG  
2951 CGGTATGGAT GCGGCGGGAC CAGAGAAAAA TCACTCAGGG TCAATGCCag  
3001 ccgaACGCCA GCAAGACGTA GCCCAGCGCG TCGGCCGCCA TGCCGGCGAT  
3051 AATGGCCTGC TTCTCGCCGA AACGTTTGGT GGCGGGACCA GTGACGAAGG  
3101 CTTGAGCGAG GCGGTGCAAG ATTCCGAATA CCGCAAGCGA CAGGCCGATC  
3151 ATCGTCGCGC TCCAGCGAAA GCGGTCTCTG CCGAAAATGA CCCAGAGCGC  
3201 TGCCGGCACC TGTCTACGA GTTGCATGAT AAAGAAGACA GTCATAAGTG  
3251 CGGCGACGAT AGTCATGCCC CGCGCCCACC GGAAGGAGCT GACTGGGTTG  
3301 AAGGCTCTCA AGGGCATCGG TCGAGATCCC GGTGCCTAAT GAGTGAGCTA  
3351 ACTTACATTA ATTGCGTTGC GCTCACTGCC CGCTTTCCAG TCGGGAAACC  
3401 TGTCGTGCCA GCTGCATTAA TGAATCGGCC AACGCGCGG GAGAGGCGGT  
3451 TTGCGTATTG GCGCCAGGG TGGTTTTTCT TTTCACCACT GAGACGGGCA  
3501 ACAGCTGATT GCCCTTCACC GCCTGGCCCT GAGAGAGTTG CAGCAAGCGG  
3551 TCCACGCTGG TTTGCCCCAG CAGGCGAAAA TCCTGTTTGA TGGTGGTTAA  
3601 CGGCGGGATA TAACATGAGC TGTCTTCGGT ATCGTCGTAT CCCACTACCG  
3651 AGATATCCGC ACCAACGCGC AGCCCGGACT CGGTAATGGC GCGCATTGCG  
3701 CCCAGCGCCA TCTGATCGTT GGCAACCAGC ATCGCAGTGG GAACGATGCC  
3751 CTCATTCAGC ATTTGCATGG TTTGTTGAAA ACCGGACATG GCACTCCAGT

3801 CGCCTTCCCG TTCCGCTATC GGCTGAATTT GATTGCGAGT GAGATATTTA  
3851 TGCCAGCCAG CCAGACGCAG ACGCGCCGAG ACAGAACTTA ATGGGCCCCG  
3901 TAACAGCGCG ATTTGCTGGT GACCCAATGC GACCAGATGC TCCACGCCCCA  
3951 GTCGCGTACC GTCTTCATGG GAGAAAATAA TACTGTTGAT GGGTGTCTGG  
4001 TCAGAGACAT CAAGAAATAA CGCCGGAACA TTAGTGCAGG CAGCTTCCAC  
4051 AGCAATGGCA TCCTGGTCAT CCAGCGGATA GTTAATGATC AGCCCACTGA  
4101 CGCGTTGCGC GAGAAGATTG TGCACCGCCG CTTTACAGGC TTCGACGCCG  
4151 CTTCGTTCTA CCATCGACAC CACCACGCTG GCACCCAGTT GATCGGCGCG  
4201 AGATTTAATC GCCGCGACAA TTTGCGACGG CGCGTGCAGG GCCAGACTGG  
4251 AGGTGGCAAC GCCAATCAGC AACGACTGTT TGCCCGCCAG TTGTTGTGCC  
4301 ACGCGGTTGG GAATGTAATT CAGCTCCGCC ATCGCCGCTT CCACTTTTTC  
4351 CCGCGTTTTT GCAGAAACGT GGCTGGCCTG GTTACCACG CGGGAAACGG  
4401 TCTGATAAGA GACACCGGCA TACTCTGCGA CATCGTATAA CGTTACTGGT  
4451 TTCACATTCA CCACCCTGAA TTGACTCTCT TCCGGGCGCT ATCATGCCAT  
4501 ACCGCGAAAG GTTTTGCGCC ATTCGATGGT GTCCCGGATC TCGACGCTCT  
4551 CCCTTATGCG ACTCCTGCAT TAGGAAGCAG CCCAGTAGTA GGTTGAGGCC  
4601 GTTGAACACC GCCGCCGCAA GGAATGGTGC ATGCCGCCCT TTCGTCTTCA  
4651 AGAATTAATT CCCAATTCCA GGCATCAAAT AAAACGAAAG GCTCAGTCGA  
4701 AAGACTGGGC CTTTCGTTTT ATCTGTTGTT TGTCGGTGAA CGCTCTCCTG  
4751 AGTAGGACAA ATCCGCCGGG AGCGGATTTG AACGTTGCGA AGCAACGGCC  
4801 CGGAGGGTGG CGGGCAGGAC GCCCGCCATA AACTGCCAGG AATTAATTCC  
4851 AGGCATCAAA TAAAACGAAA GGCTCAGTCG AAAGACTGGG CCTTTCGTTT  
4901 TATCTGTTGT TTGTCGGTGA ACGCTCTCCT GAGTAGGACA AATCCGCCGG  
4951 GAGCGGATTT GAACGTTGCG AAGCAACGGC CCGGAGGGTG GCGGGCAGGA  
5001 CGCCCGCCAT AACTGCCAG GAATTAATTC CAGGCATCAA ATAAAACGAA  
5051 AGGCTCAGTC GAAAGACTGG GCCTTTCGTT TTATCTGTTG TTTGTCGGTG  
5101 AACGCTCTCC TGAGTAGGAC AAATCCGCCG GGAGCGGATT TGAACGTTGC  
5151 GAAGCAACGG CCCGGAGGGT GCGGGCAGG ACGCCGCCA TAAACTGCCA  
5201 GGAATTAATT CCAGGCATCA AATAAAACGA AAGGCTCAGT CGAAAGACTG


5251 GGCCTTTCGT TTTATCTGTT GTTTGTCTGGT GAACGCTCTC CTGAGTAGGA  
5301 CAAATCCGCC GGGAGCGGAT TTGAACGTTG CGAAGCAACG GCCCGGAGGG  
5351 TGGCGGGCAG GACGCCCCGC ATAAACTGCC AGGAATTGGG GATCGGAATT  
5401 AATTCCTGGT TTAAACCGGG GATCTCGATC CCGCGAAATT AATACGACTC  
5451 ACTATAGGGG AATTGTGAGC GGATAACAAT TCCCCTCTAG AAATAATTTT  
5501 GTTAACTTT AAGAAGGAGA TATAcatatg gctagctcgc gagtcgacgg  
5551 cggccgcctc gagggctctt ccTGCATCAC GGGAGATGCA CTAGTTGCCC  
5601 TACCCGAGGG CGAGTCGGTA CGCATCGCCG ACATCGTGCC GGGTGC GCGG  
5651 CCCAACAGTG ACAACGCCAT CGACCTGAAA GTCCTTGACC GGCATGGCAA  
5701 TCCCGTGCTC GCCGACCGGC TGTTCACCTC CGGCGAGCAT CCGGTGTACA  
5751 CGGTGCGTAC GGTCTGAAGGT CTGCGTGTGA CGGGCACCGC GAACCACCCG  
5801 TTGTTGTGTT TGGTCGACGT CGCCGGGGTG CCGACCCTGC TGTGGAAGCT  
5851 GATCGACGAA ATCAAGCCGG GCGATTACGC GGTGATTCAA CGCAGCGCAT  
5901 TCAGCGTCGA CTGTGCAGGT TTTGCCCGCG GAAAACCCGA ATTTGCGCCC  
5951 ACAACCTACA CAGTCGGCGT CCCTGGACTG GTGCGTTTCT TGGAAGCACA  
6001 CCACCGAGAC CCGGACGCCC AAGCTATCGC CGACGAGCTG ACCGACGGGC  
6051 GGTCTACTA CGCGAAAGTC GCCAGTGTCA CCGACGCCGG CGTGCAGCCG  
6101 GTGTATAGCC TTCGTGTCGA CACGGCAGAC CACGCGTTTA TCACGAACGG  
6151 GTTCGTCAGC CACGCTACTG GCCTCACC GG TCTGAACTCA GGCCTCACGA  
6201 CAAATCCTGG TGTATCCGCT TGGCAGGTCA ACACAGCTTA TACTGCGGGA  
6251 CAATTGGTCA CATATAACGG CAAGACGTAT AAATGTTTGC AGCCCCACAC  
6301 CTCCTTGGA GGATGGGAAC CATCCAACGT TCCTGCCTTG TGGCAGCTTC  
6351 AATGActgca ggaaggGGAT CCGGCTGCTA ACAAAGCCCC AAAGGAAGCT  
6401 GAGTTGGCTG CTGCCACCGC TGAGCAATAA CTAGCATAAC CCCTTG GGGC  
6451 CTCTAAACGG GTCTTGAGGG GTTTTTTGCT GAAAGGAGGA ACTATATCCG  
6501 GAT

Figure 6  
*Hpa* I ligation



# Figure 7

Western blots of Proteins Ligated to a Biotinylated Peptide



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**